Clinical trials: Movement Abnormalities
Parkinson's Disease
A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease
This is a multicenter, parallel-group, rater-blinded, randomized clinical study in subjects with advanced PD investigating the efficacy, PK, safety and tolerability of continuous SC infusion of 2 dosing regimens of ND0612H, a…
- Trial name
- NCT02577523
- Testing
- ND0612 (Levodopa/Carbidopa solution), ND0612 (Levodopa/Carbidopa solution) + morning oral IR-LD/CD
- Where
- 11 sites in United States, Austria and 2 more
- Volunteers
- 38 people
- Sponsor
- NeuroDerm Ltd.
Neurogenic Orthostatic Hypotension, Autonomic Failure
Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients
The purpose of this study is to learn more about the effects of abdominal compression and the medication midodrine, two interventions used for the treatment of orthostatic hypotension (low blood pressure on standing), on…
- Conditions
- Neurogenic Orthostatic Hypotension, Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy
- Trial name
- NCT04620382
- Testing
- Midodrine, Abdominal compression
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Vanderbilt University Medical Center
Tourette Syndrome, Tic Disorders
Median Nerve Stimulation Pilot
Results from the University of Nottingham suggested that rhythmic median nerve stimulation (MNS) improves tic symptoms in Tourette syndrome (TS).
- Conditions
- Tourette Syndrome, Tic Disorders, Tic Disorder, Chronic Motor or Vocal
- Trial name
- MNS (NCT04731714)
- Testing
- Rhythmic median nerve stimulation, Arrhythmic median nerve stimulation
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Washington University School of Medicine
Parkinson's Disease
A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients
To investigate the safety of once-daily repeated transdermal administration of SPM 962 within a dose range of 4.5 to 36.0 mg/day (54-week treatment period) in Parkinson's disease (PD) patients treated concomitantly with L-dopa in…
- Trial name
- NCT01631825
- Testing
- SPM 962
- Where
- 8 sites in Japan
- Volunteers
- 321 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Excessive Daytime Sleepiness, Parkinson Disease
BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness
This phase 2b study is designed as multicentre, multinational, randomized, double blind, parallel group and placebo controlled with three doses of Bavisant (0.5, 1, and 3 mg/d) in subjects with excessive daytime sleepiness with…
- Trial name
- CASPAR (NCT03194217)
- Testing
- BEN-2001
- Where
- United States
- Volunteers
- 244 people
- Sponsor
- BenevolentAI Bio
Parkinson's Disease
Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine
This is a Phase 3b, open-label, multicenter trial to assess the safety and tolerability of switching from ropinirole therapy to the rotigotine transdermal system and its effect on symptoms in subjects with idiopathic Parkinson's…
- Trial name
- NCT00593606
- Testing
- Rotigotine
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- UCB Pharma
Parkinson's Disease
Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
This is a multi-center, randomized, double-blind, placebo-controlled, parallel-group study of E2007 in levodopa treated Parkinson's disease patients with motor fluctuations.
- Trial name
- NCT00368108
- Testing
- 2 mg perampanel, 4 mg perampanel
- Where
- 114 sites in United States, Canada
- Volunteers
- 752 people
- Sponsor
- Eisai Inc.
Huntington's Disease
Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BN82451B versus placebo after oral administration twice daily (bid) for 28 days in patients with Huntington's Disease…
- Trial name
- NCT02231580
- Testing
- BN82451B
- Where
- Germany
- Volunteers
- 17 people
- Sponsor
- Ipsen
Parkinson's Disease
Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease
The purpose of the research study is to determine if rasagiline is an effective treatment for fatigue in patients with Parkinson's disease (PD).
- Trial name
- REST (NCT01168596)
- Testing
- Rasagiline
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Florida
Conversion Disorder
Neuroimaging Biomarkers of Prognosis in Motor Functional Neurological Disorders
Functional Neurological Disorder (FND/ Conversion Disorder) is a highly prevalent and disabling neuropsychiatric condition. Motor FND symptoms include Nonepileptic Seizures, Functional Movement Disorders and Functional Weakness.
- Trial name
- NCT03398070
- Testing
- Standard of Care
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Parkinson's Disease
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
Inflammation plays a central role in Parkinson's disease. The use of anti-inflammatory drugs was found to reduce the risk of PD . Niacin may play an important role in reducing inflammation in PD.
- Trial name
- NCT03462680
- Testing
- niacin
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- VA Office of Research and Development
Parkinson's Disease
Highly Challenging Balance Program to Reduce Fall Rate in PD
This study will test the hypothesis that two highly challenging exercise programs, one based at the VA medical center and the other conducted remotely, will both significantly reduce overall fall rates in patients with…
- Trial name
- NCT03972969
- Testing
- Facility-based structured exercise, Home-based structured exercise, Health education
- Where
- United States
- Volunteers
- 162 people
- Sponsor
- VA Office of Research and Development
Parkinson Disease
Trial of Xyrem for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson's Disease (PD)
This clinical trial is designed to evaluate the safety and potential efficacy of Xyrem for the treatment of excessive daytime sleepiness (EDS) and nocturnal sleep disturbance in patients with mild to moderate Parkinson's Disease…
- Trial name
- Xyrem (NCT00641186)
- Testing
- sodium oxybate
- Volunteers
- 30 people
- Sponsor
- Baylor College of Medicine
Dementia With Lewy Bodies
Dementia With Lewy Bodies - Infinitome
Dementia with Lewy bodies (DLB) is the second most common cause of dementia and is associated with parkinsonism, hallucinations, and cognitive fluctuations.
- Trial name
- NCT04773041
- Testing
- Infinitome
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- HealthPartners Institute
Parkinson Disease, Early Parkinson's Disease
A Phase 3 Study With P2B001 in Subjects With Early Parkinson's
P2B001 is an investigational drug that comprised of low doses of two drugs, pramipexole and rasagiline, which are both approved drugs and routinely used in standard therapy for Parkinson's disease.
- Trial name
- NCT03329508
- Testing
- P2B001 0.6/0.75 mg, Rasagiline 0.75 mg, Pramipexole 0.6 mg
- Where
- 72 sites in United States, Canada and 2 more
- Volunteers
- 544 people
- Sponsor
- Pharma Two B Ltd.
Focal Dystonia
Quantifying Musical Performance After Treatment With Myobloc in Musician's Dystonia
This study uses a computerized method of musical instrument digital interface (MIDI) quantification of performance before and after treatment with botulinum toxin type B (Myobloc ®, Solstice Neurosciences).
- Trial name
- NCT00208091
- Testing
- Botulinum toxin, type B
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Columbia University
Parkinson Disease
Intranasal Insulin in Parkinson's Disease
This project will investigate exploratory outcomes related to the effect of intranasal insulin on cognition, mood, apathy and motor performance of subjects with Parkinson's disease over a 3 week period.
- Trial name
- INI-PD (NCT04251585)
- Testing
- Regular Novolin R
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- HealthPartners Institute
Parkinson's Disease, Deep Brain Stimulation Surgery
Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus
The purpose of this research study is to find out whether dexmedetomidine changes brain cell activity in the subthalamic nucleus (STN).
- Trial name
- NCT01721460
- Testing
- Dexmedetomidine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Wisconsin, Madison
Parkinson's Disease
Deep Brain Stimulation Effects on Gait and Balance in Patients With Parkinson's Disease
The purpose of this study is to evaluate the effect of Deep Brain stimulation (DBS) on walking in patients with Parkinson's disease that have had DBS.
- Trial name
- NCT02022735
- Testing
- Deep Brain Stimulator
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Miami
Parkinson Disease
Computational Modeling of 60 Hz Subthalamic Nucleus Deep Brain Stimulation for Gait Disorder in Parkinson's Disease
The objective of this study is to further the understanding and application of 60Hz subthalamic deep brain stimulation (STN-DBS) in Parkinson's patients with gait disorder.
- Trial name
- NCT04184791
- Testing
- Deep Brain Stimulation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Northwell Health